KLK3 and prostate cancer: In a retrospective study including 1,106 patients, Stish et al. reported a significant improvement in metastasis-free survival and prostate cancer specific survival when post-RP patients with BCR received SRT at PSA levels ≤ 0.5 ng/mL (16).